Md. Code Regs. 10.13.03.02

Current through Register Vol. 51, No. 25, December 13, 2024

Section 10.13.03.02 - Definitions

A. In this chapter, the following terms have the meanings indicated.

B. Terms Defined.

(1) "Co-prescribed" means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at an elevated risk of overdose.

(2) "Department" means the Maryland Department of Health.

(3) "Monitored prescription drug" means a prescription drug that contains a Schedule II, Schedule III, Schedule IV, or Schedule V controlled dangerous substance designated under Criminal law Article, Title 5, Subtitle 4, Annotated Code of Maryland.

(4) "Opioid overdose reversal drug" means a drug that:

(a) Rapidly reverses the respiratory depressant effects of an opioid medication; and

(b) Is approved by the federal Food and Drug Administration for the treatment of a known or suspected opioid overdose.

(5) "Prescribing licensed health care provider" means an individual who is authorized by law to prescribe a monitored prescription drug.

(6) "Riskfactor" means a characteristic, condition, behavior, or any variable that increases the likelihood of developing a disease or injury.

(7) "Secretary" means the Secretary of the Maryland Department of Health.

(8) Targeted Patient Population.

(a) "Targeted patient population" means an individual likely to experience or witness an opioid overdose.

(b) "Targeted patient population" includes, but is not limited to, an individual who:

(i) Is being prescribed opioids for acute, if appropriate, or chronic pain;

(ii) Is being treated for an opioid use disorder;

(iii) Is receiving a prescription for an opioid and a benzodiazepine; or

(iv) Resides or spends time with an individual who is prescribed opioids, misuses opioids, or has an opioid use disorder.

Md. Code Regs. 10.13.03.02

Regulation .02 adopted effective 46:12 Md. R. 541, eff. 6/17/2019